SCHEMBL6923380

SCHEMBL6923380

Cc1cc(C(=O)NC2CCCCC2)c(C)n1-c1ccc(Cl)cc1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.78
▸ NPC1 O15118 4/20 0.78
▸ RAB9A P51151 4/20 0.78
▸ ALDH1A1 P00352 4/20 0.78
▸ HPGD P15428 3/20 0.78
▸ CNR2 P34972 7/20 0.78
▸ KDM4E B2RXH2 2/20 0.75
▸ NPSR1 Q6W5P4 2/20 0.75
▸ MEN1 O00255 1/20 0.75
▸ KMT2A Q03164 1/20 0.75
▸ TP53 P04637 1/20 0.69
▸ CNR1 P21554 6/20 0.58
▸ NOTUM Q6P988 1/20 0.58
▸ MAPT P10636 2/20 0.58
▸ USP14 P54578 1/20 0.56
▸ USP7 Q93009 1/20 0.56
▸ MAPK1 P28482 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17949724 0.90 RAB9A (0.82) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL6923383 0.89 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL19749162 0.88 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL23559409 0.82 USP14 (0.65) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL17949745 0.82 USP14 (0.65) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL6921620 0.79 USP14 (0.63) SMN1; SMN2ALDH1A1CNR2NPSR1CNR1
SCHEMBL17949737 0.79 RAB9A (0.65) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL13739702 0.78 USP14 (0.65) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL23559457 0.77 USP14 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL23559530 0.77 USP14 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 — — US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 — — US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 — — US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 — — EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 — — US disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 — — US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 — — US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 — — US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 — — US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 — — US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 — — WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 — — US disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 — — US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 SMN1; SMN2 1593/4885NPC1 813/4885RAB9A 1746/4885
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885NPC1 2643/4885RAB9A 2509/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 SMN1; SMN2 307/4885NPC1 2654/4885RAB9A 2464/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885NPC1 2643/4885RAB9A 2509/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 SMN1; SMN2 544/4885NPC1 3460/4885RAB9A 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback